

# Michael J Root

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5671524/publications.pdf>

Version: 2024-02-01

17  
papers

658  
citations

759233

12  
h-index

940533

16  
g-index

17  
all docs

17  
docs citations

17  
times ranked

894  
citing authors

#	ARTICLE	IF	CITATIONS
1	Regulation of epitope exposure in the gp41 membrane-proximal external region through interactions at the apex of HIV-1 Env. <i>PLoS Pathogens</i> , 2022, 18, e1010531.	4.7	3
2	Altered Env conformational dynamics as a mechanism of resistance to peptide-triazole HIV-1 inactivators. <i>Retrovirology</i> , 2021, 18, 31.	2.0	3
3	Characterization of resistance to a potent d-peptide HIV entry inhibitor. <i>Retrovirology</i> , 2019, 16, 28.	2.0	5
4	Complex interplay of kinetic factors governs the synergistic properties of HIV-1 entry inhibitors. <i>FASEB Journal</i> , 2018, 32, .	0.5	0
5	Complex interplay of kinetic factors governs the synergistic properties of HIV-1 entry inhibitors. <i>Journal of Biological Chemistry</i> , 2017, 292, 16498-16510.	3.4	17
6	Site-Specific Polymer Attachment to HR2 Peptide Fusion Inhibitors against HIV-1 Decreases Binding Association Rates and Dissociation Rates Rather Than Binding Affinity. <i>Bioconjugate Chemistry</i> , 2017, 28, 701-712.	3.6	4
7	Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer. <i>PLoS Pathogens</i> , 2016, 12, e1006098.	4.7	32
8	Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus. <i>PLoS Pathogens</i> , 2016, 12, e1005983.	4.7	43
9	Mechanism of Multivalent Nanoparticle Encounter with HIV-1 for Potency Enhancement of Peptide Triazole Virus Inactivation. <i>Journal of Biological Chemistry</i> , 2015, 290, 529-543.	3.4	46
10	Evaluation of the efficiency of human immune system reconstitution in NSG mice and NSG mice containing a human HLA.A2 transgene using hematopoietic stem cells purified from different sources. <i>Journal of Immunological Methods</i> , 2015, 422, 13-21.	1.4	34
11	Design of a Potent $\alpha$ -Peptide HIV-1 Entry Inhibitor with a Strong Barrier to Resistance. <i>Journal of Virology</i> , 2010, 84, 11235-11244.	3.4	146
12	Asymmetric Deactivation of HIV-1 gp41 following Fusion Inhibitor Binding. <i>PLoS Pathogens</i> , 2009, 5, e1000674.	4.7	54
13	Interactions of HIV-1 Inhibitory Peptide T20 with the gp41 N-HR Coiled Coil. <i>Journal of Biological Chemistry</i> , 2009, 284, 3619-3627.	3.4	49
14	Topical application of entry inhibitors as "virstats" to prevent sexual transmission of HIV infection. <i>Retrovirology</i> , 2008, 5, 116.	2.0	22
15	Kinetic Dependence to HIV-1 Entry Inhibition. <i>Journal of Biological Chemistry</i> , 2006, 281, 25813-25821.	3.4	68
16	HIV-1 gp41 as a Target for Viral Entry Inhibition. <i>Current Pharmaceutical Design</i> , 2004, 10, 1805-1825.	1.9	91
17	Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 5016-5021.	7.1	41